Evidence map›Paper›PMID 35078405›Full record

ArticleBMC gastroenterology2022

Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time.

Waleed Alghamdi, Khaled Lotfy, Corinne Weernink, Enad Alsolami, Anthony Jevnikar, Patrick Luke, Anton Skaro, Karim Qumosani, Mayur Brahmania, Paul Marotta and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Excellence in Organ Utilisation-A Quantitative and Qualitative Evidence Base for a New Approach in the UK.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Waleed AlghamdiDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. dr.waleed.alghamdi@gmail.com.
Khaled LotfyDivision of Nephrology, Department of Medicine, Western University, London, ON, Canada.
Corinne WeerninkMultiorgan Transplant Program, London Health Sciences Centre, London, ON, Canada.
Enad AlsolamiDepartment of Internal Medicine, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Anthony JevnikarDivision of Nephrology, Department of Medicine, Western University, London, ON, Canada.
Patrick LukeDepartment of Surgery, Western University, London, ON, Canada.
Anton SkaroDepartment of Surgery, Western University, London, ON, Canada.
Karim QumosaniDivision of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
Mayur BrahmaniaDivision of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
Paul MarottaDivision of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
Syed M Hosseini-MoghaddamDivision of Infectious Diseases, Department of Medicine, Western University, London, ON, Canada.
Anouar TeriakyDivision of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
London Health Sciences Centre · CAWestern University · CAJeddah University · SAKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransplantation offers the best survival for patients with end stage organ disease. Transplant of hepatitis C virus (HCV) nucleic acid test (NAT) positive organs into negative recipients is a novel strategy that can expand the donor pool. We aim to evaluate our centre's experience.

methodsWe preformed a retrospective review of anti-HCV NAT positive and negative organs into negative recipients transplanted over 27 months. Primary outcome was the success rate of eradication of HCV post-transplant. Secondary outcomes were rate of transmission of HCV, treatment adverse events, and graft failure.

results33 anti-HCV positive organs were transplanted into negative recipients. 22 (66.7%) were NAT positive. Median recipients age was 49 years (interquartile range [IQR] 44.5-62.0) with the majority being males (57.6%). NAT positive organ transplantations included 16 kidneys, 3 livers, 1 kidney-pancreas, 1 liver-kidney, and 1 heart. The most common HCV genotype was 1a (59.1%). The median time to initiating therapy was 41.5 days. SVR12 was 100% in patients who finished therapy. There were no adverse events with therapy and no graft failure.

conclusionsAnti-HCV NAT positive organ transplantation into negative recipients is safe with excellent eradication rates and no significant adverse events or graft failure. This would expand donor pool to close the gap between supply and demand.

Indexed as

Hepatitis COrgan TransplantationCanadaHepacivirusHumansMaleMiddle AgedRetrospective StudiesHepatitis COrgan transplantation

Identifiers

PMID35078405
PMCPMC8787881
OpenAlexW4206943075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.